Compare 10X Genomics Inc (TXG) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? 10X Genomics Inc trades at $67.8 (market cap $8.55B), while State Street Real Estate Select Sector SPDR ETF trades at $43.42. The key difference: 10X Genomics Inc is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| TXG | XLRE | |
|---|---|---|
Market Cap | $8.55B | — |
Sector | Health | Sector/Thematic |
52-Week High | $67.29 | $46.01 |
52-Week Low | $11.34 | $40.01 |
Enterprise Value | $8.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
XLRE trades at $43.9, down 0.05% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings, with RSI near oversold levels. Recent news highlights real estate's resilience amid inflation, though some analysts warn of underperformance versus AI-focused alternatives. Dividend safety remains a focus, with a future dividend scheduled for June 2026.
Outlook is mixed; real estate offers diversification and income potential, but high interest rates and sector rotation pose risks. Investors should weigh XLRE's low expense ratio and U.S. focus against macroeconomic headwinds. Sentiment is cautious, with technical weakness suggesting near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
